Breast cancer, dietary lignan intake, and CYP17 polymorphism.

被引：0
|
作者：
McCann, SE [1 ]
Moysich, KB [1 ]
Freudenheim, JL [1 ]
Ambrosone, CB [1 ]
Shields, PG [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY 14214 USA
来源：
AMERICAN JOURNAL OF EPIDEMIOLOGY | 2001年 / 153卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
64
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [41] CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients
    Ohnishi, T
    Ogawa, Y
    Saibara, T
    Nishioka, A
    Kariya, S
    Fukumoto, M
    Onishi, S
    Yoshida, S
    ONCOLOGY REPORTS, 2005, 13 (03) : 485 - 489
  • [42] CYP17 promoter polymorphism and breast cancer in Australian women under forty years of age.
    Spurdle, AB
    Chen, X
    Hopper, J
    Easton, D
    Dite, G
    Cui, J
    McCredie, M
    Southey, M
    Venter, D
    Chenevix-Trench, G
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 97 - 97
  • [43] The T/C polymorphism of the CYP17 gene and G/A polymorphism of the CYP19 gene in endomletrial cancer
    Szyllo, K.
    Smolarz, B.
    Romanowicz-Makowska, H.
    Lewy, J.
    Kulig, B.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2006, 25 (03): : 411 - 416
  • [44] CYP17 polymorphisms and prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 182 - 182
  • [45] The Association of the CYP19 and CYP17 Polymorphic Markers with Sporadic Breast Cancer
    V. V. Artamonov
    L. N. Lyubchenko
    M. A. Shabanov
    O. V. Babenko
    M. V. Nemtsova
    D. V. Zaletaev
    Molecular Biology, 2003, 37 : 830 - 835
  • [46] Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany
    Vesovic, Z
    Herkommer, K
    Vogel, W
    Paiss, T
    Maier, C
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1303 - 1307
  • [47] The association of the CYP19 and CYP17 polymorphic markers with sporadic breast cancer
    Artamonov, VV
    Lyubchenko, LN
    Shabanov, MA
    Babenko, OV
    Nemtsova, MV
    Zaletaev, DV
    MOLECULAR BIOLOGY, 2003, 37 (06) : 830 - 835
  • [48] The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer
    Haiman, CA
    Stampfer, MJ
    Giovannucci, E
    Ma, J
    Decalo, NE
    Kantoff, PW
    Hunter, DJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (07) : 743 - 748
  • [49] Within-family analyses of polymorphism effects, adjusted for familial factors, with application to CYP17 and breast cancer
    Cui, JS
    Spurdle, AB
    Due, GS
    Southey, MC
    Venter, DJ
    McCredie, MRE
    Giles, GG
    Chenevix-Trench, G
    Hopper, JL
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1224S - 1224S
  • [50] CYP17 and breast cancer:: no overall effect, but what about interactions?
    Little, J
    Simard, J
    BREAST CANCER RESEARCH, 2005, 7 (06): : 238 - 242
12345